Dodge & Cox Funds®

International Stock Fund

To Our Shareholders

The Dodge & Cox International Stock Fund had a total return of 11.0% for the year ended December 31, 2021, compared to a return of 11.3% for the MSCI EAFE (Europe, Australasia, Far East) Index.

Market Commentary

International equity markets rose over the first half of 2021 and then seesawed in the second half amid concerns about inflation and COVID-19 variants. Overall, international developed markets posted strong results for the year. Economic growth in most developed market countries has rebounded to above pre-pandemic levels. However, the MSCI Emerging Markets Index declined 3%. China's stock market, in particular, dropped 22% due to a slowing economy and the government's increased regulations across multiple industries. Internet-related companies were notably impacted, and the CSI China Internet Index tumbled 49%.

Valuations are above historical averages for the overall market, embedding expectations of continued earnings recovery. Wide valuation disparities remain between value and growth stocks,[a] as well as between the beneficiaries and victims of low interest rates. The MSCI EAFE Value Index currently trades at only 10.8 times forward earnings compared to a lofty 25.5 times for the MSCI EAFE Growth Index.[b] This market divergence is a remarkable 3.8 standard deviations above the historical average. Meanwhile, the valuation spread between stocks benefiting or suffering from low interest rates is at the all-time highest level since the International Stock Fund's inception in 2001. This valuation spread is extraordinary given the remarkably low level of nominal and real interest rates, and it reflects more certainty about the likelihood of interest rates staying lower for longer than we believe is merited.

Investment Strategy

We believe these wide valuation disparities continue to provide attractive opportunities for active, value-oriented investment managers like Dodge & Cox. As a result of our individual stock selection, the Fund is diversified and exposed to various investment drivers. The Fund's portfolio can be divided into three similarly sized groups.

First, the Financials and Energy sectors constitute large portions of both the value and "low-rate victims" cohorts, and they currently comprise 34% of the Fund. In 2021, we actively trimmed many of the Fund's holdings in these sectors as they outperformed the overall market. Nevertheless, the Fund remains meaningfully overweight Financials and Energy. The Fund's Financials holdings are inexpensive, well capitalized, and could return meaningful amounts of capital to shareholders in 2022. Although rising interest rates are not a core part of our investment thesis, rate increases could further propel earnings growth. In Energy, oil prices rose 51% in 2021 as demand continued to rebound from pandemic-induced lows and exceeded supply throughout the year. Many energy companies have improved capital allocation by restraining spending on traditional oil and gas projects and returning more capital to shareholders. At current commodity prices, the Fund's energy holdings trade at attractive valuations and generate substantial free cash flow, which can be used for increased returns to shareholders.

Another third of the portfolio has exposure to innovation-led earnings growth through reasonably valued technology, internet, and health care holdings. The Fund is about 1.4 times overweight the MSCI EAFE on a combined basis in these areas of the market. We added meaningfully to the Fund's Health Care and China Internet positions throughout 2021, which we discuss in more detail below.

The final third of the portfolio is diversified among the remaining sectors, notably Consumer Staples, Consumer Discretionary (excluding internet retail companies), and Industrials. As valuations became more attractive, we added to Consumer Staples this past year. However, the Fund's exposure to these sectors is roughly half the weight of the benchmark.

Health Care

During 2021, Health Care was our largest add in the portfolio. As a result, the Fund's Health Care position increased from 12.3% at the beginning of 2021 to 17.7% at year-end. We added significantly to Sanofi, Novartis, GlaxoSmithKline, and Roche Holding—these pharmaceutical companies now represent four of the Fund's five largest positions.[c] Pharmaceuticals broadly underperformed due to concerns about potential U.S. drug pricing legislation. In addition, lower current and future growth expectations from lower diagnoses and treatment rates for non-COVID-19 conditions negatively impacted their stock prices.

The Fund's pharmaceutical holdings are attractively valued and generally trade at market multiples. Each holding has a globally diversified unique business mix and combination of earnings growth drivers, such as restructuring (GlaxoSmithKline), cost cutting (Sanofi), and/or innovation (Novartis and Roche). As a notable exception, AstraZeneca traded at a premium valuation embedding high expectations of future success, so we sold the Fund's position.

We discussed GlaxoSmithKline in our Semi-Annual 2021 Report. The company's restructuring remains on track, and management expects to spin off its Consumer Health division in the first half of 2022. We would now like to share our thoughts on Novartis, another large pharmaceutical holding at 3.4%.

---

a. Generally, stocks that have lower valuations are considered "value" stocks, while those with higher valuations are considered "growth" stocks.
b. Unless otherwise specified, all weightings and characteristics are as of December 31, 2021.
c. The use of specific examples does not imply that they are more or less attractive investments than the portfolio's other holdings.

Based in Switzerland, Novartis has leading positions in a broad array of innovative drugs, generics, and biosimilars across 155 countries. After divesting its Animal Health, Vaccines, and Consumer Health businesses and stake in Roche, Novartis is now focused on its core pharmaceutical business. Its stock price has underperformed amid concerns that the company's future growth will be challenged given its large revenue base and loss of patent exclusivity for several key products over the next five years. Despite these challenges, we are encouraged by the company's renewed focus and strong execution over the past five years, with pharmaceutical revenues up 30% and operating profit up 51%. Moreover, we believe Novartis' product diversification, robust research and development pipeline, strong balance sheet, and capable management team—when combined with a low starting valuation of 13 times forward earnings—mitigate downside risks.

In 2021, we also started positions in two new health care services holdings: Olympus (the leading endoscope manufacturer, based in Japan) and Fresenius Medical Care (one of the largest global manufacturers of dialysis products and providers of dialysis services, domiciled in Germany). These companies are attractively valued relative to their franchise strength and market leadership. Olympus has made significant progress focusing on its core endoscope franchise and expanding margins. Fresenius is restructuring to reduce costs as it manages through COVID-induced headwinds, while positioning itself to capitalize on the growing need for its dialysis services.

China Internet

The Fund's China Internet holdings have significantly underperformed since February, when regulatory actions in China increased in pace and severity. Investors fear that growth and profitability will be severely curtailed. More recently, slowing economic growth in China and plans to delist China ADRs from U.S. exchanges weighed on share prices in China.

How do we evaluate the investment merits in the face of these uncertainties? By remaining disciplined in applying our bottom-up investment approach. We consider a range of possible scenarios based on our in-depth due diligence with the company management teams, internet industry experts, legal experts, and China policy experts. Our International Equity Investment Committee then weighs and debates our analysts' scenario forecasts against the current valuations to discern what risks might already be priced in, and the potential investment opportunities relative to the overall portfolio.

We revisited our investment theses and reaffirmed our view that they remain attractive long-term investments, despite the changing regulatory environment. We recently added to Alibaba, Baidu, and JD.com. The following three factors gave us the confidence to increase the Fund's exposure to these holdings. First, some of the government's policies are similar to other data privacy and anti-monopoly policies around the world. Second, important government officials and publications have sought to clarify the government's agenda and stress the importance of private enterprise. Each of these holdings has significant investments in valuable, high-growth new businesses (e.g., Cloud at Alibaba, Autonomous Driving at Baidu) that are key to the government's technological leadership aspirations. Third, we believe the valuations of these companies have priced in significant pessimism. In our view, valuations remain attractive (at an almost five-year low) and embed more conservative assumptions of growth and profitability. China Internet collectively comprised 7.2% of the Fund on December 31.[d]

In Closing

We are enthusiastic about the opportunities we see as a value-oriented, active manager. We believe the Fund's portfolio is well positioned, especially with the valuation gaps between value and growth stocks, as well as between the beneficiaries and victims of low interest rates, as wide as they are today. Valuation changes can occur swiftly and without warning, so we encourage our shareholders to maintain a long-term perspective. Thank you for your continued confidence in our firm. As always, we welcome your comments and questions.

For the Board of Trustees,

Charles F. Pohl,
Chairman

Dana M. Emery,
President

February 1, 2022

d. China Internet comprises Alibaba, Baidu, JD.com, Naspers, Prosus, and Tencent.

DODGE & COX FUNDS®

December 31, 2021

International Stock Fund

TICKER SYMBOL
DODFX

Objectives

- The Fund seeks long-term growth of principal and income.

Strategy

- The Fund invests primarily in a diversified portfolio of equity securities issued by non-U.S. companies from at least three different countries, including emerging market countries. The Fund is not required to allocate its investments in set percentages in particular countries. The Fund typically invests in medium-to-large well established companies based on standards of the applicable market.

Risks

- The Fund is subject to market risk, meaning holdings in the Fund may decline in value for extended periods due to the financial prospects of individual companies or due to general market and economic conditions. Investing in non-U.S. securities may entail risk due to foreign economic and political developments; this risk may be higher when investing in emerging markets. Please read the prospectus for specific details regarding the Fund's risk profile.

General Information

Net Asset Value Per Share	$47.29
Total Net Assets (billions)	$44.1
2021 Expense Ratio	0.62%
Expense Ratio per 5/1/21 Prospectus	0.63%
2021 Portfolio Turnover Rate	18%
30-Day SEC Yield[a]	1.76%
Active Share[b]	90%
Number of Companies	71
Fund Inception	2001
No sales charges or distribution fees	

Investment Manager: Dodge & Cox, San Francisco. Managed by the International Equity Investment Committee, whose seven members' average tenure at Dodge & Cox is 22 years.

Asset Allocation



Portfolio Characteristics

	Fund	MSCI EAFE
Median Market Capitalization (billions)	**$40**	$15
Weighted Average Market Capitalization (billions)	**$84**	$84
Price-to-Earnings Ratio[c]	**10.5x**	15.3x
Countries Represented	**21**	21
Emerging Markets (Brazil, China, India, Mexico, Peru, Russia, South Africa, South Korea)[d][g]	**16.8%**	0.0%

Region Diversification (% Market Value)[d][g]

	Fund	MSCI EAFE
Europe (excluding United Kingdom)	**39.8**	51.1
United Kingdom	**16.4**	14.6
Asia Pacific (excluding Japan)	**13.4**	11.1
Japan	**11.6**	22.5
Canada	**6.1**	0.0
United States	**5.9**	0.0
Latin America	**3.9**	0.0
Africa	**0.6**	0.0
Middle East	**0.0**	0.7

Ten Largest Equity Holdings (% Market Value)[d][e]

	Fund
GlaxoSmithKline PLC (United Kingdom)	**4.0**
Sanofi (France)	**3.8**
UBS Group AG (Switzerland)	**3.4**
Novartis AG (Switzerland)	**3.4**
Roche Holding AG (Switzerland)	**3.3**
BNP Paribas SA (France)	**3.0**
Samsung Electronics Co., Ltd. (South Korea)	**2.9**
ICICI Bank, Ltd. (India)	**2.9**
Banco Santander SA (Spain)	**2.6**
Barclays PLC (United Kingdom)	**2.4**

*Total issuer exposure, including notional exposure of total return swaps, is 3.0% for Prosus NV (Netherlands). Portfolio totals may not sum to 100%.

Sector Diversification (% Market Value)[d]

	Fund	MSCI EAFE
Financials	**26.6**	16.9
Health Care	**17.7**	12.8
Materials	**10.2**	7.6
Consumer Discretionary	**9.2**	12.5
Energy	**7.7**	3.4
Information Technology	**7.1**	9.7
Industrials	**6.9**	16.2
Communication Services	**4.8**	4.5
Consumer Staples	**4.7**	10.3
Real Estate	**2.3**	2.8
Utilities	**0.5**	3.4

*Total sector exposure, including the notional exposure of equity total return swaps, is Consumer Discretionary at 10.5% and Communication Services at 3.8% . Portfolio totals may not sum to 100%.

(a) SEC Yield is an annualization of the Fund's net investment income for the trailing 30-day period. Dividends paid by the Fund may be higher or lower than implied by the SEC Yield.
(b) Active share is a measure of how much an investment portfolio differs from its benchmark index, based on a scale of 0% (complete overlap with the index) to 100% (no overlap). Overlap for each security in the Fund is the lower of either its percentage weight in the Fund or its percentage weight in the relevant index. Active share is calculated as 100% minus the sum of the overlapping security weights.
(c) Price-to-earnings (P/E) ratios are calculated using 12-month forward earnings estimates from third-party sources as of the reporting period. Estimates reflect a consensus of sell-side analyst estimates, which may lag as market conditions change.
(d) Excludes derivatives.
(e) The Fund's portfolio holdings are subject to change without notice. The mention of specific securities is not a recommendation to buy, sell, or hold any particular security and is not indicative of Dodge & Cox's current or future trading activity.
(f) Net Cash & Other includes cash, short-term investments, unrealized gain (loss) on derivatives, receivables, and payables.
(g) The Fund may classify a company in a different category than the MSCI EAFE. The Fund generally classifies a company based on its country of incorporation, but may designate a different country in certain circumstances.

Average Annual Total Return[1]

For periods ended December 31, 2021	1 Year	3 Years	5 Years	10 Years
Dodge & Cox International Stock Fund	11.02%	11.65%	7.19%	7.58%
MSCI EAFE Index	11.26	13.54	9.55	8.03

dodgeandcox.com

Returns represent past performance and do not guarantee future results. Investment return and share price will fluctuate with market conditions, and investors may have a gain or loss when shares are sold. Fund performance changes over time and currently may be significantly lower than stated above. Performance is updated and published monthly. Visit the Fund's website at dodgeandcox.com or call 800-621-3979 for current month-end performance figures.

The Dodge & Cox International Stock Fund's total return was 2.4% for the fourth quarter of 2021, compared to 2.7% for the MSCI EAFE (Europe, Australasia, Far East) Index. For the twelve months ended December 31, 2021, the Fund generated a total return of 11.0%, compared to 11.3% for the MSCI EAFE.

Investment Commentary

International equity markets rose over the first half of 2021 and then seesawed in the second half amid concerns about inflation and COVID-19 variants. Overall, international developed markets posted strong results for the year. Economic growth in most developed market countries has rebounded to above pre-pandemic levels. However, the MSCI Emerging Markets Index declined 3%. China's stock market, in particular, dropped 22% due to the Chinese government's increased regulations across multiple industries. Internet-related companies were notably impacted, and the CSI China Internet Index tumbled 49%.

Valuations are above historical averages for the overall market, embedding expectations of continued earnings recovery. Wide valuation disparities remain between value and growth stocks,[2] as well as between the beneficiaries and victims of low interest rates. The MSCI EAFE Value Index currently trades at only 10.8 times forward earnings compared to a lofty 25.5 times for the MSCI EAFE Growth Index.[3] This market divergence is a remarkable 3.8 standard deviations above the historical average. Meanwhile, the valuation spread between stocks benefiting or suffering from low interest rates is at the all-time highest level since the International Stock Fund's inception in 2001. This valuation spread is extraordinary given the incredibly low level of nominal and real interest rates, and it reflects more certainty about the likelihood of interest rates staying lower for longer than we believe is merited.

We believe these two wide valuation disparities continue to provide attractive opportunities for active, value-oriented, bottom-up investment managers like Dodge & Cox. In particular, the Financials and Energy sectors constitute large portions of both the value and "low-rate victims" cohorts, and they currently account for 34% of the Fund. In 2021, we actively trimmed many of the Fund's holdings as they outperformed the overall market. Nevertheless, the Fund remains meaningfully overweight Financials and Energy. The Fund's Financials holdings are inexpensive, well capitalized, and on track to return meaningful amounts of capital to shareholders in 2022. Although rising interest rates are not a core part of our investment thesis, increases could further propel earnings growth. In Energy, capital return potential is also poised to increase, as oil prices have risen and management teams have restrained capital spending.

Another third of the portfolio has exposure to innovation-led earnings growth through reasonably valued technology, internet, and health care holdings. The Fund is about 1.4 times overweight the MSCI EAFE on a combined basis in these areas of the market. During 2021, Health Care was our largest add in the portfolio. As a result, the Fund's Health Care position increased from 12.3% at the beginning of 2021 to 17.7% at year-end. We added significantly to Sanofi, Novartis, GlaxoSmithKline, and Roche Holding—these pharmaceutical companies now represent four of the Fund's five largest positions.[4] We also started positions in two new health care services holdings: Olympus (the leading endoscope manufacturer, based in Japan) and Fresenius Medical Care (one of the largest global manufacturers of dialysis products and providers of dialysis services, domiciled in Germany).

The final third of the portfolio is diversified among the remaining sectors, notably Consumer Staples, Consumer Discretionary (excluding internet retail companies), and Industrials. As valuations became more attractive, we added meaningfully to Consumer Staples this past year. Nevertheless, the Fund's exposure to these sectors is roughly half the weight of the benchmark.

We are enthusiastic about the opportunities we see as a value-oriented, active manager. As always, we remain focused on the long term, and encourage our shareholders to do so as well. Thank you for your continued confidence in Dodge & Cox.

Fourth Quarter Performance Review

The Fund underperformed the MSCI EAFE by 0.3 percentage points during the quarter.

Key Detractors from Relative Results

- The Fund's emerging market holdings—especially Alibaba, Itau Unibanco, Axis Bank, and Grupo Televisa—detracted from results.
- The Fund's holdings within the Consumer Discretionary sector (down 5% compared to up 3% for the MSCI EAFE sector), such as Honda Motor, led to relative underperformance.
- The Fund's average overweight in Financials (28% versus 17%) and its holdings within the sector (down 1% compared to up 1% for the MSCI EAFE sector), including Banco Santander and Prudential UK, led to relative underperformance.
- Mitsubishi Electric was an additional key detractor.

Key Contributors to Relative Results

- The Fund's holdings in the Health Care sector (up 8% compared to up 3% for the MSCI EAFE sector) helped performance. GlaxoSmithKline and Roche Holding were particularly strong.
- In Energy, the Fund's relative outperformance (up 8% compared to down 1% for the MSCI EAFE sector) contributed positive results. Suncor Energy did particularly well.
- In Industrials, the Fund's holdings (up 7% compared to up 3% for the MSCI EAFE sector), especially Johnson Controls International, contributed to performance.
- Additional key contributors included UBS Group, Nutrien, and TE Connectivity.

2021 Performance Review

The Fund underperformed the MSCI EAFE by 0.2 percentage points in 2021.

Key Detractors from Relative Results

- The Fund's China internet holdings in the Consumer Discretionary and Communication Services sectors—namely Alibaba, Naspers, Baidu, and Prosus—detracted from results.
- The Fund's holdings within the Information Technology sector (flat compared to up 20% for the MSCI EAFE sector), especially Samsung Electronics, led to relative underperformance.
- Additional detractors included Credit Suisse, Itau Unibanco, and Mitsubishi Electric.

Key Contributors to Relative Results

- The Fund's average overweight position (8% versus 3%) and holdings in the Energy sector (up 50% compared to up 23% for the MSCI EAFE sector), especially Ovintiv and Suncor Energy, led to relative outperformance.
- In Materials, the Fund's outperformance (up 30% compared to up 10% for the MSCI EAFE sector) contributed to results, notably Glencore and Nutrien.
- Additional key contributors included Johnson Controls International, ICICI Bank, BNP Paribas, UBS Group, and GlaxoSmithKline.

1 The Fund's total returns include the reinvestment of dividend and capital gain distributions, but have not been adjusted for any income taxes payable by shareholders on these distributions or on Fund share redemptions. Index returns include dividends but, unlike Fund returns, do not reflect fees or expenses. The MSCI EAFE (Europe, Australasia, Far East) Index is a broad based, unmanaged equity market index aggregated from 21 Developed Market country indices, excluding the United States and Canada. Results reflect dividends net of withholding taxes. MSCI makes no express or implied warranties or representations and shall have no liability whatsoever with respect to any MSCI data contained herein. The MSCI data may not be further redistributed or used as a basis for other indices or any securities or financial products. This report is not approved, reviewed, or produced by MSCI. All returns are stated in U.S. dollars, unless otherwise noted.

2 Generally, stocks that have lower valuations are considered "value" stocks, while those with higher valuations are considered "growth" stocks.

3 Unless otherwise specified, all weightings and characteristics are as of December 31, 2021.

4 The use of specific examples does not imply that they are more or less attractive investments than the portfolio's other holdings.

Before investing in any Dodge & Cox Fund, you should carefully consider the Fund's investment objectives, risks, and charges and expenses. To obtain a Fund's prospectus and summary prospectus, which contain this and other important information, visit dodgeandcox.com or call 800-621-3979. Please read the prospectus and summary prospectus carefully before investing.